Literature DB >> 18657424

Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor.

Lorenzo Maggi1, Francesca Andreetta, Carlo Antozzi, Paolo Confalonieri, Ferdinando Cornelio, Vidmer Scaioli, Renato Mantegazza.   

Abstract

Thymoma-associated myasthenia gravis is considered a more severe disease compared with non-thymomatous myasthenia gravis and is generally associated with antibodies to the acetylcholine receptor (AChR-Ab). Even though a single case of thymoma-associated myasthenia gravis with anti-muscle specific kinase (MuSK) antibodies has been reported, to our knowledge, seronegative thymoma-associated myasthenia gravis has not been described. We report on two cases of this disease without antibodies to AChR or MuSK as a further evidence of the variability of myasthenia gravis in terms of antibody profile and thymic pathological findings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657424     DOI: 10.1016/j.nmd.2008.06.368

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

Review 1.  Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.

Authors:  Elizabeth A Lippner; David B Lewis; William H Robinson; Tamiko R Katsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-06-22

Review 2.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

3.  Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Authors:  Sukhmani K Padda; Xiaopan Yao; Alberto Antonicelli; Jonathan W Riess; Yue Shang; Joseph B Shrager; Robert Korst; Frank Detterbeck; James Huang; Bryan M Burt; Heather A Wakelee; Sunil S Badve
Journal:  J Thorac Oncol       Date:  2017-11-27       Impact factor: 15.609

4.  Early-Onset Myasthenia Gravis Following COVID-19 Vaccination.

Authors:  Myung Ah Lee; Chonghwee Lee; Jung Hyun Park; Jung Hwan Lee
Journal:  J Korean Med Sci       Date:  2022-03-14       Impact factor: 2.153

5.  Myasthenia gravis as a prognostic marker in patients with thymoma.

Authors:  Bernardo Cacho-Díaz; Karen Salmerón-Moreno; Nydia A Lorenzana-Mendoza; Julia Texcocano; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.